Bio­Marin may have lost the bat­tle in DMD ri­val­ry, but it won a $35M ar­gu­ment with Sarep­ta

Bio­Marin $BM­RN may have lost big on their ex­pen­sive and high-pro­file bid to get an OK for a trou­bled Duchenne mus­cu­lar dy­s­tro­phy drug, but the West Coast biotech is get­ting a con­so­la­tion prize from Sarep­ta — the big win­ner so far in the US with its mar­ket­ed drug Ex­ondys 51.

Sarep­ta $SRPT is pay­ing Bio­Marin $35 mil­lion to set­tle their scrap over rights to ex­on-skip­ping tech, re­serv­ing some 5% and 8% roy­al­ty streams for cer­tain ex­on-skip­ping ther­a­pies. And new Sarep­ta CEO Doug In­gram laud­ed the fact that the biotech now has “world­wide free­dom” to op­er­ate on a drug that it whol­ly con­trols.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER